Revelation Biosciences, Inc. (REVBW)
- Business Wire
Revelation Biosciences Inc. Announces Mandatory Unit Separation to Occur on January 13, 2023
SAN DIEGO, January 10, 2023--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), announced today that, on January 13, 2023, the Company’s units, which trade with the ticker symbol "REVBU" will be mandatorily separated and the units will no longer trade on the Nasdaq Capital Market. Each unit is comprised of one share of the Company’s common stock and one warrant that entitles the holder to purchase one share of common stock at price of $11.50 per share. In the separation,
- Business Wire
Revelation Biosciences Inc. Announces Future Clinical Development Plans Based on Recent Biomarker Analysis and Significant Reduction in New Collagen Deposition (Fibrosis) in Preclinical Model
SAN DIEGO, Calif., November 18, 2022--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced that recently completed exploratory biomarker analysis has confirmed clinical development plans for REVTx-300 in the treatment of CKD and AKI. This new biomarker data is in addition to the previously-announced significant reduction in
- Business Wire
Revelation Biosciences Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Recent Corporate Progress
SAN DIEGO, November 10, 2022--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reported its third quarter 2022 financial results and highlighted recent corporate progress.
